Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 known ✓ | O43570 | 2/20 | 0.50 |
| ▸ | CA1 known ✓ | P00915 | 2/20 | 0.50 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.50 |
| ▸ | RAD51 | Q06609 | 6/20 | 0.61 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.50 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.50 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17255097 | 1.00 | RAD51 (0.61) | RAD51ENPP2CA12CA1CA2 | |
| SCHEMBL4057351 | 1.00 | RAD51 (0.61) | RAD51ENPP2CA12CA1CA2 | |
| SCHEMBL9321648 | 0.86 | ENPP2 (0.74) | ENPP2CA12CA1CA2CA9 | |
| SCHEMBL14437899 | 0.86 | ENPP2 (0.74) | ENPP2CA12CA1CA2CA9 | |
| SCHEMBL31389389 | 0.85 | RAD51 (0.72) | RAD51CA12CA1CA2CA9 | |
| SCHEMBL15282738 | 0.84 | ENPP2 (0.72) | ENPP2CA12CA1CA2CA9 | |
| SCHEMBL17255098 | 0.84 | ENPP2 (0.72) | ENPP2CA12CA1CA2CA9 | |
| SCHEMBL26977995 | 0.84 | ENPP2 (0.72) | ENPP2CA12CA1CA2CA9 | |
| SCHEMBL15210455 | 0.83 | MAPT (0.54) | RAD51CA12CA1CA2CA9 | |
| SCHEMBL31389377 | 0.82 | RAD51 (0.70) | RAD51APEX1MAPTTP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144801-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MUSCLE CONDITIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4605585-A2 | METHODS FOR DETECTING ANTI-PORCINE ANTIBODIES | New York University (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250250548-A1 | METHODS AND COMPOSITIONS FOR TREATING NEGATIVE-SENSE SINGLE-STRANDED RNA VIRUS | THE UNIVERSITY OF CHICAGO (US) | 2025-08-07 | — | — | US | disclosed |
| US-20250195637-A1 | VACCINE COMPOSITION AGAINST TWO RESPIRATORY VIRUSES | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2025-06-19 | — | — | US | disclosed |
| US-20250082784-A1 | FORMULATIONS FOR SMALL INTESTINAL DELIVERY OF RSV AND NOROVIRUS ANTIGENS | VAXART, INC. | 2025-03-13 | — | — | US | disclosed |
| US-12227769-B2 | Methods and compositions for treating negative-sense single-stranded RNA virus | THE UNIVERSITY OF CHICAGO (US) | 2025-02-18 | — | — | US | disclosed |
| US-12186407-B2 | Formulations for small intestinal delivery of RSV and norovirus antigens | VAXART, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-12181735-B2 | Optical element or polarizing plate, and eyewear using same | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2024-12-31 | — | — | US | disclosed |
| US-12138306-B2 | FcRn-targeted mucosal vaccination against RSV | UNIVERSITY OF MARYLAND (US) | 2024-11-12 | — | — | US | disclosed |
| US-20240315989-A1 | METHODS OF TREATING COVID-19 | WASHINGTON UNIVERSITY | 2024-09-26 | — | — | US | disclosed |
| US-20220229315-A1 | Optical Element Or Polarizing Plate, And Eyewear Using Same | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2022-07-21 | — | — | US | disclosed |
| US-20220220157-A1 | ADENOVIRUS POLYNUCLEOTIDES AND POLYPEPTIDES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-07-14 | — | — | US | disclosed |
| CN-114730029-A | Polarized light emitting element, polarized light emitting panel and display device | 日本化药株式会社 | 2022-07-08 | — | — | CN | disclosed |
| US-11376317-B2 | FcRn-targeted mucosal vaccination against RSV | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2022-07-05 | — | — | US | disclosed |
| WO-2022125686-A1 | PRECISION ENGINEERING OF A CELLULAR SENSE-AND-RESPONSE FUNCTION | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF COMMERCE (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20220183308-A1 | HUMAN MILK PRODUCTS USEFUL IN PRE- AND POST-OPERATIVE CARE | HAYFIN SERVICES LLP, AS COLLATERAL AGENT (GB) | 2022-06-16 | — | — | US | disclosed |
| US-11344041-B2 | Human milk products useful in pre- and post-operative care | PROLACTA BIOSCIENCE, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20220088169-A1 | VIRUS VACCINE | GRIFFITH UNIVERSITY (AU) | 2022-03-24 | — | — | US | disclosed |
| EP-3971636-A1 | OPTICAL ELEMENT OR POLARIZING PLATE, AND EYEWEAR USING SAME | Nippon Kayaku Kabushiki Kaisha (JP) | 2022-03-23 | — | — | EP | disclosed |
| US-11254711-B2 | Adenovirus polynucleotides and polypeptides | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376317-B2 | FcRn-targeted mucosal vaccination against RSV | FCGRT, FCGR3B, FCGR2A | CA12 1937/4885CA1 3270/4885CA2 3542/4885 |
| US-12138306-B2 | FcRn-targeted mucosal vaccination against RSV | FCGRT, FCGR3B, FCGR2A | CA12 1937/4885CA1 3270/4885CA2 3542/4885 |
| US-20240315989-A1 | METHODS OF TREATING COVID-19 | SIGMAR1, HTR1A, SGMS1 | CA12 3697/4885CA1 3576/4885CA2 2642/4885 |
| US-20260144801-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MUSCLE CONDITIONS | CPT1B, HPGD, PTGES | CA12 4105/4885CA1 3654/4885CA2 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.